We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Takeda and Ovid Therapeutics on Wednesday announced a global collaboration to jointly develop and commercialise the Japanese company's experimental selective CH24H inhibitor TAK-935 for the treatment of rare paediatric epilepsies.